Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin
Open Access
- 10 June 2009
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 146 (1), 120-122
- https://doi.org/10.1111/j.1365-2141.2009.07715.x
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Long‐term follow‐up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained responseBritish Journal of Haematology, 2009
- Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 studyBlood, 2008
- Profound Hypogammaglobulinemia 7 Years after Treatment for Indolent LymphomaCancer Investigation, 2008
- Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic PurpuraAnnals of Internal Medicine, 2007
- B cell depletion therapy in rheumatic diseaseBest Practice & Research Clinical Rheumatology, 2006
- Enteroviral meningoencephalitis in a patient with non-Hodgkin's lymphoma treated previously with rituximabInternational Journal of Laboratory Hematology, 2006
- Enteroviral Meningoencephalitis after Anti‐CD20 (Rituximab) TreatmentClinical Infectious Diseases, 2003